Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. - Wikidata - awgldk - TriplyDB

Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.

Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.

http://www.wikidata.org/entity/Q36589096

about

Pleiotropic effects of statins in the diseases of the liver Is There Any Evidence for a Role of Local Treatment in Cholangiocarcinoma?Cancer review: Cholangiocarcinoma Cholangiocarcinoma Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma Systematic review: Preventive and therapeutic applications of metformin in liver disease Liver masses: a clinical, radiologic, and pathologic perspective.Hepatitis B virus infection and intrahepatic cholangiocarcinoma.Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients.Methylated Bone Morphogenetic Protein 3 (BMP3) Gene: Evaluation of Tumor Suppressor Function and Biomarker Potential in Biliary Cancer.Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Statin use and risk of liver cancer: an update meta-analysis.Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma.Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study.Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma.Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control study.Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation.Meta-analysis of studies using statins as a reducer for primary liver cancer risk.Outcomes of Hepatic Resection in Intrahepatic Cholangiocarcinoma Patients with Diabetes, Hypertension, and Dyslipidemia: Significance of Routine Follow-Up.Guideline approach to therapy in patients with newly diagnosed type 2 diabetes.Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.New and emerging treatment options for biliary tract cancer.Overweight, obesity and the risk of gallbladder and extrahepatic bile duct cancers: A meta-analysis of observational studies.Metformin Inhibits Migration and Invasion of Cholangiocarcinoma Cells Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma.Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation.The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: A hospital based case-control study.Aspirin use and the risk of cholangiocarcinoma.Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Characteristics and outcomes of cholangiocarcinoma by region in Thailand: A nationwide study.Type II diabetes mellitus is associated with a reduced risk of cholangiocarcinoma in patients with biliary tract diseases.Analyzing risk factors for intrahepatic cholangiocarcinoma.Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.Smoking and risk of cholangiocarcinoma: a systematic review and meta-analysis.New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin.Metformin does not improve survival of cholangiocarcinoma patients with diabetes.

P2860

Q26741176-D5194B7D-125E-4132-9349-9C9A6B83D0CA Q26796522-BF34942A-DF6D-4FED-8B7C-3D680F0FA4DF Q26865200-73B2F97E-CD77-41DA-ACC3-41D9CFC99E8E Q27001694-F20FCD65-8C67-4C41-998F-463B8403A46F Q28076535-78DEF2E8-B74B-4047-AD0A-EBDB09DA62FF Q28085535-F9B3158E-1CA5-4897-92A3-278612BB7354 Q30403670-8F6F4CE0-6742-48B3-A152-923A6830A73D Q33626806-BB142C00-B7DE-4CEF-8FC6-B1977F0D7FCA Q33672932-DBF85EE4-8273-4F0D-9E17-B557567368E5 Q33955013-DFA443AD-21E1-4921-B0EF-5C01A35D8162 Q34135248-591140FD-9467-4E3C-A358-93CA1615A0E3 Q34198230-99455819-A356-4605-830E-A37E9397699F Q34324683-FC6E03D0-6F0F-480C-80C1-BF8455392C7D Q34446161-3325D0A6-06B4-438A-AD9A-46DE83E04219 Q34775377-C89980B0-A5B0-4436-9EEC-170FA41C3126 Q34874988-3932FBB4-3B92-4AEF-AAB5-1B1A662AD45D Q35550204-ABBD0356-CC4C-42B2-BFA5-A1BC9A770DEE Q36125495-958C1F78-E4BD-45B2-B06D-EC123F9B91D3 Q36250109-E62F863E-5500-4404-8619-AE6D35DB3045 Q36442895-14148741-9998-4274-B614-B5E4562D9206 Q36919251-88999515-34BF-4DBF-9631-3C4BB541AAC0 Q37000684-9A13A96E-A330-4612-9E5D-F08E45DB2065 Q37577111-A6CAD4A3-58FB-487F-A387-A5182F017E1F Q37671148-5498A437-4D4D-4124-B400-3526169557E2 Q38160836-7C88A7E2-28C6-4642-890B-F33EF91BF66A Q38378989-6FCC46F7-9DB6-4E90-8AF6-5887F2C348E7 Q38710382-125ADB5C-8A65-4259-B185-A9C28A53A5B7 Q38874166-0513B357-C761-4DB9-B817-0775E33D3E64 Q38942795-83AA64ED-567A-4A7B-B1B5-0AF94A579876 Q38999875-D1E9CA61-5007-443B-AAAD-DF0BD73F9F4A Q40842861-7E8BE016-B427-4C7C-8B15-A07FC91A0FE6 Q40873283-5C367410-91D6-4569-9A9F-92591B2C7AF2 Q41991379-2B397C3A-E312-4142-B8CE-C4F8AE5CB141 Q42868486-B70BA65F-4535-4CF8-9709-2440111108D2 Q45041783-ADB9B488-1175-4BC0-AE08-A808915D770D Q46764293-069922ED-049D-4C47-BBF5-EC5A22337684 Q47140374-546ACBAF-0238-4F14-89F1-453FA223FD8E Q47141943-CEE28A1D-C8D2-4B2B-8385-957617985872 Q50050635-EB1912B8-7182-46DD-812F-D4C5B8D0729F Q50449005-F6EFA784-C667-4CE5-BC72-D0FBA909E8CB

P2860

Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.

http://www.wikidata.org/entity/Q36589096

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Risk factors for intrahepatic ...... n use and reduced cancer risk.

@ast

Risk factors for intrahepatic ...... n use and reduced cancer risk.

@en

type

label

Risk factors for intrahepatic ...... n use and reduced cancer risk.

@ast

Risk factors for intrahepatic ...... n use and reduced cancer risk.

@en

prefLabel

Risk factors for intrahepatic ...... n use and reduced cancer risk.

@ast

Risk factors for intrahepatic ...... n use and reduced cancer risk.

@en

P1433

Q36589096-B60018A4-5E95-462E-BB60-35AD2C761D97

P1476

Q36589096-C02DB8C8-3558-4788-8104-A77EFC00F1AA

P2093

Q36589096-0D16D3CE-B61C-4190-AB8E-10A5275670DB

Q36589096-120120A0-1608-428A-A840-52C849F33428

Q36589096-223695AF-26E8-4B22-B230-8EA2F2EAB3A3

Q36589096-23095DE9-232E-4D69-89A1-03840C109FED

Q36589096-249FA7C8-BD52-461B-955B-FDA1EC91A2F3

Q36589096-536763A2-1C38-4226-B1DD-5553D1F6CBDE

Q36589096-6AB5A725-F336-4F66-BE8D-295EAB6E45E5

Q36589096-84C4B71D-645D-48B2-9C36-D198F0DF23F1

Q36589096-A7B8C489-494E-48F8-840A-0A036F3F5D12

Q36589096-D5E37AF1-4673-44FA-A8B5-39DCD74E3286

P2860

Q36589096-01286516-55C1-4135-9CE3-747EBD446090

Q36589096-221B5D1B-EA7D-41FB-B030-0C9B199ABD5A

Q36589096-2759968A-D927-41BA-A131-DAF19E899215

Q36589096-27E103DF-B738-4359-9C4B-B55DE0614098

Q36589096-2A493CEA-C383-4EEB-AE4F-8C890BE49CFD

Q36589096-33040053-DD33-43B7-A801-B6A35F09DE8E

Q36589096-4CF456D2-C0C3-4357-847B-8C35C6BC1185

Q36589096-58889D5D-F12B-4CFD-842A-99534F95C6A0

Q36589096-64550D2B-55EB-44BB-B778-D99D600630AF

Q36589096-665E3C55-4359-4EBB-A786-E31356BDBE5B

P304

Q36589096-442E1C84-9527-44BB-884A-FBECF4CC35DD

P31

Q36589096-6B98D17E-C3C9-4BA0-A8F9-6DA04203A350

P356

Q36589096-9D880233-7776-44A6-8F05-63B604992724

P407

Q36589096-82F362D4-5366-4C0F-8658-D8E64C2A2148

P433

Q36589096-998942B4-8F83-4A16-801A-08974C3BF22A

P478

Q36589096-38EEE708-5A13-412E-91BC-7AE3429052FA

P50

Q36589096-14F59557-FAA1-494C-B129-3E1393E53ED3

P577

Q36589096-F9650400-3B1B-4882-9F9F-1A8EE3BF8CAC

P698

Q36589096-EA276221-DE4A-429B-87FA-9A853CBD4146

P921

Q36589096-491C1ADA-E8F5-48D5-8230-F496461C761D

Q36589096-C397D13F-E50B-4B2F-8D74-3CF435D09513

P932

Q36589096-261BE5F2-3978-47C6-943C-521D8A394D73

P356

P1433

P1476

Risk factors for intrahepatic ...... n use and reduced cancer risk.

@en

P2093

Janet E Olson

http://www.w3.org/2001/XMLSchema#string

Ju Dong Yang

http://www.w3.org/2001/XMLSchema#string

Lewis R Roberts

http://www.w3.org/2001/XMLSchema#string

Roongruedee Chaiteerakij

http://www.w3.org/2001/XMLSchema#string

Rosebud O Roberts

http://www.w3.org/2001/XMLSchema#string

Seth W Slettedahl

http://www.w3.org/2001/XMLSchema#string

Teresa A Mettler

http://www.w3.org/2001/XMLSchema#string

Terry M Therneau

http://www.w3.org/2001/XMLSchema#string

W Ray Kim

http://www.w3.org/2001/XMLSchema#string

William S Harmsen

http://www.w3.org/2001/XMLSchema#string

P2860

The Measurement of Observer Agreement for Categorical Data

Diabetes and cancer: a consensus report.

Epidemiology of the metabolic syndrome in the USA

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.

Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy.

Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma.

P304

648-655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.26092

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Gregory J Gores

P577

2012-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23055147

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

3565026

http://www.w3.org/2001/XMLSchema#string